FDA Denies Majority Of Requests To Reclassify Low-Risk De Novo Devices
This article was originally published in The Gray Sheet
Close to 63% of requests to FDA seeking Class I or Class II status for de novo devices without a predicate have been denied to date, FDA staffers say.
You may also be interested in...
FDA may indicate in future "not substantially equivalent" 510(k) letters whether or not the sponsor's device is a likely candidate for placement in Class I or Class II using the new alternative low-risk de novo device classification process established by Sec. 207 of the FDA Modernization Act.
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.